Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany

Breast care

Thomas Mittendorf¹  Thomas Menschik¹  Johann-Matthias von Schulenburg¹  Wolfgang Greiner¹  Sebastian Braun¹ 

[1] aCentre for Health Economics, Leibniz University of Hanover, Germany

关键词: Aromatase inhibitors;    Postmenopause;    Cost effectiveness;    Breast cancer;    Early stage;   

DOI  :  10.1159/000255840

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Medical studies have shown that switching to exemestane after 2-3 years of adjuvant treatment with tamoxifen is effective when looking at overall survival. No cost effectiveness study of exemestane has been conducted in the German health care context.

【 授权许可】

Unknown